Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by K Liu
Q2 2024 Earnings Forecast for Peraso Inc. (NASDAQ:PRSO) Issued By K LIU &
Peraso Inc. (NASDAQ:PRSO – Free Report) – Analysts at K LIU & increased their Q2 2024 EPS estimates for Peraso in a research note issued to investors on Wednesday, July 17th. K LIU & analyst K. Liu now expects that the company will post earnings of ($0.73) per share for the quarter, up from their previous forecast of ($0.81). The consensus estimate for Peraso’s current full-year earnings is ($2.89) per share. K LIU & also issued estimates for Peraso’s FY2024 earnings at ($2.81) EPS.
FY2024 Earnings Forecast for DHI Group, Inc. (NYSE:DHX) Issued By K LIU &
DHI Group, Inc. (NYSE:DHX – Free Report) – K LIU & increased their FY2024 earnings per share estimates for DHI Group in a report released on Thursday, November 2nd. K LIU & analyst K. Liu now anticipates that the technology company will post earnings per share of $0.29 for the year, up from their prior estimate of $0.18. The consensus estimate for DHI Group’s current full-year earnings is $0.06 per share. Get DHI Group alerts: DHX has been the subject of a number of other research reports.
Q4 2024 EPS Estimates for Devon Energy Co. Boosted by Analyst (NYSE:DVN)
Devon Energy Co. (NYSE:DVN – Free Report) – Equities research analysts at Zacks Research boosted their Q4 2024 earnings estimates for Devon Energy in a note issued to investors on Thursday, November 2nd. Zacks Research analyst J. Saha now anticipates that the energy company will post earnings of $1.65 per share for the quarter, up from their prior forecast of $1.51. The consensus estimate for Devon Energy’s current full-year earnings is $5.94 per share.
Leerink Partnrs Weighs in on BioMarin Pharmaceutical Inc.’s Q4 2024 Earnings (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) – Analysts at Leerink Partnrs raised their Q4 2024 earnings estimates for BioMarin Pharmaceutical in a note issued to investors on Thursday, November 2nd. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings of $0.37 per share for the quarter, up from their previous forecast of $0.36. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.25 per share.
The Cigna Group to Post FY2024 Earnings of $28.17 Per Share, Cantor Fitzgerald Forecasts (NYSE:CI)
The Cigna Group (NYSE:CI – Free Report) – Equities research analysts at Cantor Fitzgerald cut their FY2024 EPS estimates for The Cigna Group in a note issued to investors on Friday, November 3rd. Cantor Fitzgerald analyst S. James now anticipates that the health services provider will post earnings per share of $28.17 for the year, down from their previous estimate of $28.23. Cantor Fitzgerald currently has a “Neutral” rating and a $334.00 price target on the stock.
FY2024 EPS Estimates for Axalta Coating Systems Ltd. (NYSE:AXTA) Boosted by KeyCorp
Axalta Coating Systems Ltd. (NYSE:AXTA – Free Report) – Equities research analysts at KeyCorp lifted their FY2024 earnings estimates for shares of Axalta Coating Systems in a research report issued to clients and investors on Wednesday, November 1st. KeyCorp analyst A. Yefremov now anticipates that the specialty chemicals company will post earnings per share of $2.06 for the year, up from their prior forecast of $1.96.
FY2024 Earnings Forecast for DHI Group, Inc. Issued By K LIU & (NYSE:DHX)
DHI Group, Inc. (NYSE:DHX – Free Report) – Investment analysts at K LIU & upped their FY2024 earnings estimates for DHI Group in a report released on Thursday, November 2nd. K LIU & analyst K. Liu now forecasts that the technology company will post earnings of $0.29 per share for the year, up from their prior forecast of $0.18. The consensus estimate for DHI Group’s current full-year earnings is $0.06 per share.
Q3 2023 EPS Estimates for Aquestive Therapeutics, Inc. (NASDAQ:AQST) Reduced by Analyst
Q3 2023 EPS Estimates for Aquestive Therapeutics, Inc. (NASDAQ:AQST) Reduced by Analyst Aquestive Therapeutics, Inc. (NASDAQ:AQST – Free Report) – Equities research analysts at Wedbush decreased their Q3 2023 earnings per share estimates for Aquestive Therapeutics in a research report issued to clients and investors on Wednesday, August 9th. Wedbush analyst A. Argyrides now expects that the company will post earnings of ($0.12) per share for the quarter, down from their prior estimate of ($0.10).
[Incidence and clinical characteristics of engraftment syndrome after syngeneic hematopoietic stem cell transplantation in patients with hematological diseases]. - Physician's Weekly
To explore the incidence and clinical characteristics of engraftment syndrome (ES) after syngeneic hematopoietic stem cell transplantation (syn-HSCT) in patients with hematological diseases. The clinical data of 21 patients who received syn-HSCT at People’s Hospital of Peking University from January 1994 to May 2018 were retrospectively analyzed. Seven (33.3% ) of 21 patients developed ES.
FY2022 Earnings Estimate for Peraso Inc. (NASDAQ:PRSO) Issued By K LIU &
Peraso Inc. (NASDAQ:PRSO – Get Rating) – Research analysts at K LIU & boosted their FY2022 earnings per share estimates for shares of Peraso in a research report issued to clients and investors on Tuesday, November 15th. K LIU & analyst K. Liu now expects that the company will post earnings per share of ($1.05) for the year, up from their prior estimate of ($1.13). The consensus estimate for Peraso’s current full-year earnings is ($1.13) per share.
Are health-care policies restricting further progress in cancer survival outcomes?
We commend Melina Arnold and colleagues on the ICBP SURVMARK-2 project published in The Lancet Oncology, which concluded that cancer survival has improved over the past two decades (1995–2014) across seven high-income countries because of earlier diagnosis and advancements in tailored treatments based on molecular markers.A noteworthy finding was that survival is persistently lower in the UK and Denmark compared with the other countries for four common cancer types.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with K
Contact K, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack